Financial Performance - For the year ending December 31, 2025, the company reported a net loss of approximately RMB 68.4 million, a decrease of 26.7% compared to a net loss of RMB 93.3 million in 2024[4] - The basic and diluted loss per share for 2025 was RMB 0.29, compared to RMB 0.36 in 2024[4] - The net loss before tax for the group was RMB 96,003,000 in 2025, compared to RMB 93,324,000 in 2024, indicating a slight increase in losses[28] - The net loss for 2025 was RMB 68.4 million, a decrease from RMB 93.3 million in 2024, indicating an improvement in financial performance[65] Revenue and Sales - The company recorded revenue of RMB 44.9 million for the year, attributed to the launch of the Iberis® RDN system, which was approved for use in treating resistant hypertension[4] - Total revenue for 2025 reached RMB 44,932 thousand, with customer contract revenue from medical product sales contributing RMB 44,076 thousand[19] - Major customer A contributed RMB 42,472 thousand to the revenue in 2025, representing over 10% of total revenue[17] - The company reported revenue of RMB 44.9 million for 2025, a significant increase from RMB 0 in 2024, primarily driven by the commercialization of RDN products[54] Research and Development - Research and development expenses for the year were approximately RMB 61.9 million, an increase of 49.9% from RMB 41.3 million in 2024[4] - R&D expenses increased to RMB 61.9 million in 2025 from RMB 41.3 million in 2024, driven by higher third-party contract costs related to DCB and RDN product development[59] - The company is focused on research and development of its core product, Bioheart®, and related technologies[104] Assets and Liabilities - Total assets less current liabilities amounted to RMB 807.4 million as of December 31, 2025, compared to RMB 714.1 million in 2024[6] - The company’s total liabilities increased to RMB 25.0 million in 2025 from RMB 19.6 million in 2024[6] - The company’s non-current assets totaled RMB 450.6 million as of December 31, 2025, compared to RMB 434.7 million in 2024[6] - The company reported a significant increase in non-current liabilities, totaling RMB 195,348 thousand in 2025 compared to RMB 33,594 thousand in 2024[7] Cash Flow and Expenditures - Cash and cash equivalents as of December 31, 2025, were approximately RMB 92.3 million, a decrease of 54.4% from RMB 202.4 million as of December 31, 2024[4] - The net cash used in operating activities for the year ended December 31, 2025, was RMB 67.7 million, primarily due to R&D and administrative expenses[66] - The net cash used in investment activities was RMB 196.0 million, mainly due to the purchase of RMB 230.0 million in time deposits[67] - The company's capital expenditures significantly dropped from RMB 47.1 million in 2024 to RMB 7.6 million in 2025, primarily due to the completion of previous production facility purchases[68] Corporate Governance - The board recognizes the importance of good corporate governance and has adopted the corporate governance code as its own[95] - The audit committee, composed of three independent non-executive directors, is responsible for reviewing and supervising the company's financial reporting procedures and internal controls[99] - The annual performance of the group has been reviewed and deemed compliant with applicable accounting standards and regulations[100] Market and Product Development - The Iberis® RDN system completed its first commercial procedure in Europe in February 2025[4] - The company has successfully obtained market access for the Iberis® second-generation RDN system in multiple countries, including China, France, Germany, and Italy[51] - The Bioheart® BRS system is in the registration phase in China, with expected approval from the National Medical Products Administration in Q3 2026[45] - The company is focused on addressing unmet medical needs in coronary artery disease and resistant hypertension through innovative interventional cardiovascular devices[42] Employee and Operational Costs - Employee costs, excluding directors and key management personnel, increased to RMB 12,910,000 in 2025 from RMB 11,136,000 in 2024, reflecting a rise of 15.9%[23] - The company's total employee benefits expenses for the reporting period amounted to approximately RMB 129.1 million[76] - The company employed 65 full-time employees as of December 31, 2025, all based in China[76] Strategic Plans and Future Outlook - The company aims to become a globally recognized chronic disease management medical device platform, with a focus on advancing its core products and expanding its market presence[52] - The company plans to establish a new production facility in Jiaxing, Zhejiang Province, expected to be operational by 2026[50] - The company is actively seeking external collaborations, strategic investments, and acquisition opportunities to facilitate future expansion[58] Other Financial Information - The group reported a total of RMB 18,707,000 in other expenses for 2025, down from RMB 33,913,000 in 2024, reflecting a decrease of 44.7%[24] - Financial costs rose to RMB 8,742,000 in 2025 from RMB 64,000 in 2024, marking a substantial increase due to interest on redeemable liabilities[25] - The group has unrecognized deferred tax assets amounting to RMB 785,223,000 as of December 31, 2025, down from RMB 826,103,000 in 2024[29] - The company recorded a tax credit of RMB 27.6 million for the year 2025, compared to none in 2024[64]
百心安(02185) - 2025 - 年度业绩